Rticc
Seleccione idioma:  
Buscar:
RTICC 2013
Programas RTICC
Agenda
Seguimiento cientifico
Programas RTICC » Cáncer de colon » Introducción
 
INTRODUCTION

Colon cancer is the third most common cancer and the second cause of cancer death in developed countries. Colorectal cancer (CRC), when men and women are considered together, is the most frequent cancer in Spain, where every year more than 19,000 new cases are diagnosed. Nowadays, the life-time cumulative risk is about 6% and overall 5-year survival is around 50%, but this depends enormously on the stage at diagnosis. Prognosis is very poor for stage IV (20%), and these patients are treated with different lines of chemotherapy and targeted therapies than involve anti VEGF and EGFR treatments which are very expensive to the health care system. Pancreatic ductal adenocarcinoma is one of the most aggressive cancers and remains a largely incurable disease. It represents about 10% of all gastrointestinal malignancies, and it is the fourth leading cause of cancer death overall. It is the tumor in which less progress has been made at the clinical level in the last 50 years. Gastric cancer is currently the 5th leading cause of cancer-related death in both sexes, with rates of 12.94 and 5.65 in men and women, respectively in Spain with important geographic differences: some Spanish regions present mortality rates that are much higher than the European mean, while others show rates among the lowest in the continent. + more...

OBJECTIVES

EXCELLENCE, INNOVATION AND TECHNOLOGY TRANSFER

FUNCTIONAL STRUCTURE OF THE PROGRAMME

SYNERGIES

ADDED VALUE OF THE RESEARCH GROUPS

MANAGEMENT OF THE PROGRAM

IMPACT AND TRANSFER

SCHEME OF EVALUATION OF THE PROGRAMME

Timeline of tasks related to specific WPs

Introducción
Coordinador
Grupos
Work Packages
Publicaciones
Proyectos
Ensayos clínicos
Otros resultados
Agenda
Enlaces
Intranet
Noticias
03/03/2017 | Otras reuniones
13/11/2016 | Otras reuniones
Publicaciones
RD12/0036/0023
NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.
Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, Nadeu F, Enjuanes A, Clot G, Costa D, Carrio A, Villamor N, Colomer D, Martinez A, Bens S, Siebert R, Wotherspoon A, Beà S, Matutes E, Campo E
Am J Surg Pathol  2016.  2.  192-201.  PMID: 26426381. 
Grupos colaboradores: RD12/0036/0036 , RD12/0036/0023

RD12/0036/0023
Present and future of personalized medicine in CLL.
Montserrat E, Bauman T, Delgado J
Best Pract Res Clin Haematol  2016.  1.  100-110.  PMID: 27742064. 

RD12/0036/0023
Maintenance therapy in chronic lymphocytic leukaemia.
Delgado J, Montserrat E
Lancet Haematol  2016.  9.  e399-400.  PMID: 27570083. 

RD12/0036/0023
[Advances in the treatment of chronic lymphocytic leukaemia].
Mozas P, Delgado J
Med Clin (Barc)  2016.  10.  447-454.  PMID: 27431885. 

RD12/0036/0023
The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia.
Ortíz-Maldonado V, Mozas P, Delgado J
Ther Adv Hematol  2016.  6.  321-329.  PMID: 27904736. 

RD12/0036/0023
The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ, EHA Roadmap for European Hematology Research.
Haematologica  2016.  2.  115-208.  PMID: 26819058. 

RD12/0036/0023
Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently?
Giné E, Sehn LH
Hematol Oncol Clin North Am  2016.  6.  1179-1194.  PMID: 27888874. 

RD12/0036/0023
Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.
Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano G, Beà S, Navarro A, Kulis M, Verdaguer-Dot N, Jares P, Enjuanes A, Calasanz MJ, Bergmann A, Vater I, Salaverría I, van de Werken HJ, Wilson WH, Datta A, Flicek P, Royo R, Martens J, Giné E, Lopez-Guillermo A, Stunnenberg HG, Klapper W, Pott C, Heath S, Gut IG, Siebert R, Campo E, Martín-Subero JI
Cancer Cell  2016.  5.  806-821.  PMID: 27846393. 
Grupos colaboradores: RD12/0036/0063 , RD12/0036/0036 , RD12/0036/0023

RD12/0036/0023
Genetic evolution in chronic lymphocytic leukaemia.
Delgado J, Villamor N, López-Guillermo A, Campo E
Best Pract Res Clin Haematol  2016.  1.  67-78.  PMID: 27742073. 
Grupos colaboradores: RD12/0036/0036 , RD12/0036/0023

RD12/0036/0020
FEMALE NEWBORN WITH UNDIFFERENTIATED SARCOMA DEFINED BY BCORCCNB3 FUSION TRANSCRIPT
Martín-Vañó S, Berbegall AP, Navarro L, Blanquer-Maceiras M, Beléndez-Bieler C, Garrido-Colino C, Navarro S, Rosa Noguera Salvá
  2015. 

ISCII
ISCII
 
Ministerio de Economia y Competitividad
Descargar
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Logotipos
 
ISCII
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
|
|
|
|
 
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos
RSS